New in 2024
Here's What Was New for the 2024 Meeting!
Investor & Biopharma Partnerships Evening - Free to Attend
After a challenging year for cell therapy investment, this session spotlighted big pharma, VC and investor perspectives on the current market and opportunities, stemming a conversation on how investment into this promising space can be reinvigorated.
Speakers:
 |
 |
 |
 |
| David Fontana Chief Business & Operating Officer Umoja Biopharma |
Chris Moore Senior Vice President & General Counsel Umoja Biopharma |
Stefano Quintini Partner, Technology Transactions, Industry Co-Lead, Healthtech & Life Sciences Fenwick & West |
Miguel Forte President Elect | Entrepreneur in Residence ISCT | AdBio Partners |
C-Level Think Tank - Invitation Only
Saw an exclusive opportunity for top C-level executives to collaborate and discuss the most pressing challenges the CAR-TCR community are facing in Europe
New Topics Included:
CAR-T Applications in Autoimmunity
Expanding clinical access and pursuing a huge new population pool by harnessing CAR-T or CAR-Treg therapy to treat autoimmunity. Turbocharging durable efficacies, reviewing safety considerations, detecting surrogate biomarkers, and evaluating indications to maximise clinical outcome with Cabaletta Bio, Kyverna Therapeutics, AstraZeneca, Novartis, and Quell Therapeutics.
Non-Viral Engineering
Reviewing engineering efficiencies of non-viral methods, such as CRISPR, electroporation, LNP, and TALEN, and harnessing these novel approaches to armour cells against the TME, decrease vein-to-vein times, and cut costs of production with Cellectis, Genome Frontier Therapeutics, Anocca, Arsenal Bio, and T-CURX.
Point of Care Manufacturing
Reinventing turnaround times, cost of goods, and accessibility through a decentralised manufacturing model approach with pioneers, Tigen Pharma. This topic discussed site onboarding and regulatory considerations to understand how you can implement this novel system.
Discovery of New Clinical Data from Next Gen Programs!
Exploration of clinical updates and biomarker data from trials demonstrating durable efficacies across solid tumours (with Franco Locatelli and Immatics), allogeneic approaches (Cellectis, Caribou Bio), and autoimmune indications (Kyverna Therapeutics, ImmPACT Bio).
New Speaking Companies Included:
